阿奇霉素、克拉霉素、左旋氧氟沙星及其他抗生素对肺炎衣原体的体外活性
In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.
作者信息
Hammerschlag M R, Qumei K K, Roblin P M
机构信息
Department of Pediatrics and Medicine, State University of New York, Brooklyn 11203.
出版信息
Antimicrob Agents Chemother. 1992 Jul;36(7):1573-4. doi: 10.1128/AAC.36.7.1573.
Abstract
The in vitro susceptibilities of 11 strains of Chlamydia pneumoniae to azithromycin, clarithromycin, erythromycin, L-oflaxacin, and doxycycline were determined. Clarithromycin was the most active agent tested, with an MIC for 90% of strains and minimal chlamydiacidal concentration for 90% of strains of 0.03 microns/ml. The activity of azithromycin was similar to those of erythromycin and doxycycline, with MICs for 90% of strains of 0.125 to 0.25 microns/ml. However, the prolonged half-life and enhanced tissue penetration of azithromycin should allow for less frequent dosing and shorter duration of therapy than with erythromycin or clarithromycin. L-Ofloxacin had activity similar to that of ofloxacin, with MICs of 0.125 to 0.5 micron/ml. From the results of this in vitro study, azithromycin and clarithromycin appear to be effective antibiotics that may have a role in the treatment of infections due to C. pneumoniae.
摘要
测定了11株肺炎衣原体对阿奇霉素、克拉霉素、红霉素、左旋氧氟沙星和强力霉素的体外敏感性。克拉霉素是所测试的活性最强的药物，90%菌株的最低抑菌浓度（MIC）和90%菌株的最低杀衣原体浓度为0.03微克/毫升。阿奇霉素的活性与红霉素和强力霉素相似，90%菌株的MIC为0.125至0.25微克/毫升。然而，阿奇霉素半衰期延长和组织穿透力增强，与红霉素或克拉霉素相比，给药频率应更低，治疗疗程应更短。左旋氧氟沙星的活性与氧氟沙星相似，MIC为0.125至0.5微克/毫升。从这项体外研究结果来看，阿奇霉素和克拉霉素似乎是有效的抗生素，可能在治疗肺炎衣原体感染中发挥作用。
相似文献
1
In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.阿奇霉素、克拉霉素、左旋氧氟沙星及其他抗生素对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1992 Jul;36(7):1573-4. doi: 10.1128/AAC.36.7.1573.
2
In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.阿奇霉素、克拉霉素、红霉素和四环素对13株肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1996 Jan;40(1):212-4. doi: 10.1128/AAC.40.1.212.
3
In vitro activity of trovafloxacin against Chlamydia pneumoniae.曲伐沙星对肺炎衣原体的体外活性。
Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033.
4
In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae.新型抗菌酮内酯类药物塞曲霉素对肺炎衣原体的体外活性
J Antimicrob Chemother. 2003 Sep;52(3):497-9. doi: 10.1093/jac/dkg371. Epub 2003 Aug 13.
5
In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.德国患者肺炎衣原体分离株的体外药敏性及抗生素联合用药的协同活性。
Antimicrob Agents Chemother. 1999 Jul;43(7):1808-10. doi: 10.1128/AAC.43.7.1808.
6
In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.阿奇霉素、克拉霉素及其他抗生素对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1996 Nov;40(11):2669-70. doi: 10.1128/AAC.40.11.2669.
7
In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae.新型酮内酯类药物泰利霉素对肺炎衣原体的体外活性
J Antimicrob Chemother. 2001 Sep;48(3):403-5. doi: 10.1093/jac/48.3.403.
8
In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe.左氧氟沙星对来自北美和欧洲的嗜肺军团菌、肺炎支原体和肺炎衣原体当代临床分离株的体外活性。
Clin Microbiol Infect. 2002 Apr;8(4):214-21. doi: 10.1046/j.1469-0691.2002.00392.x.
9
In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.新型8-甲氧基喹诺酮BAY 12-8039对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1998 Apr;42(4):951-2. doi: 10.1128/AAC.42.4.951.
10
Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.通过最低抑菌浓度（MIC）和时间杀菌曲线研究20株对青霉素敏感及耐药的肺炎球菌对左氧氟沙星、环丙沙星、氧氟沙星、红霉素、阿奇霉素和克拉霉素的敏感性。
Diagn Microbiol Infect Dis. 1997 Jul;28(3):131-7. doi: 10.1016/s0732-8893(97)00017-5.
引用本文的文献
1
A novel combination approach of human polyclonal IVIG and antibiotics against multidrug-resistant Gram-positive bacteria.一种针对多重耐药革兰氏阳性菌的人多克隆静脉注射免疫球蛋白（IVIG）与抗生素的新型联合治疗方法。
Infect Drug Resist. 2016 Dec 8;9:301-311. doi: 10.2147/IDR.S120227. eCollection 2016.
2
A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease.一项针对慢性阻塞性肺疾病频繁急性加重的成年人进行的双盲、随机、安慰剂对照研究，比较罗红霉素与多西环素联合用药、单独使用罗红霉素或匹配的安慰剂治疗12周的效果。
J Negat Results Biomed. 2015 Sep 7;14:15. doi: 10.1186/s12952-015-0034-8.
3
Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.嗜软骨沃氏菌在卡氏棘阿米巴中对抗生素的敏感性
Antimicrob Agents Chemother. 2009 Jun;53(6):2663-6. doi: 10.1128/AAC.00046-09. Epub 2009 Mar 30.
4
In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.吡咯并吡唑基取代恶唑烷酮RWJ-416457的体外抗菌活性
Antimicrob Agents Chemother. 2007 Jan;51(1):361-5. doi: 10.1128/AAC.01017-06. Epub 2006 Nov 13.
5
Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients.左氧氟沙星在重症监护患者中的药代动力学和药效学
Clin Pharmacokinet. 2005;44(6):627-35. doi: 10.2165/00003088-200544060-00004.
6
Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.左氧氟沙星：美国治疗细菌感染用药综述
Drugs. 2003;63(24):2769-802. doi: 10.2165/00003495-200363240-00008.
7
In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.利福霉素衍生物ABI-1648（利福拉齐，KRM-1648）、ABI-1657和ABI-1131对沙眼衣原体及肺炎衣原体近期临床分离株的体外活性。
Antimicrob Agents Chemother. 2003 Mar;47(3):1135-6. doi: 10.1128/AAC.47.3.1135-1136.2003.
8
Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model.克拉霉素对兔肺炎衣原体感染后早期动脉粥样硬化病变的影响
Antimicrob Agents Chemother. 2002 Aug;46(8):2321-6. doi: 10.1128/AAC.46.8.2321-2326.2002.
9
Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.阿奇霉素、克拉霉素或左氧氟沙星长期治疗对持续感染模型中肺炎衣原体的影响。
Antimicrob Agents Chemother. 2002 Feb;46(2):409-12. doi: 10.1128/AAC.46.2.409-412.2002.
10
Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.住院儿科患者常用的抗菌和抗真菌药物：基于临床药代动力学对治疗的影响
Paediatr Drugs. 2001;3(10):733-61. doi: 10.2165/00128072-200103100-00003.
本文引用的文献
1
A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections.一种新的鹦鹉热衣原体菌株，TWAR，在急性呼吸道感染中分离得到。
N Engl J Med. 1986 Jul 17;315(3):161-8. doi: 10.1056/NEJM198607173150305.
2
In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).肺炎衣原体（衣原体属TWAR株）的体外药敏试验
Antimicrob Agents Chemother. 1989 Sep;33(9):1634-5. doi: 10.1128/AAC.33.9.1634.
3
Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.氧氟沙星治疗肺炎衣原体（TWAR株）下呼吸道感染
Am J Med. 1990 Dec;89(6):722-4. doi: 10.1016/0002-9343(90)90212-v.
4
A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.一种新的呼吸道病原体：肺炎衣原体TWAR株。
J Infect Dis. 1990 Apr;161(4):618-25. doi: 10.1093/infdis/161.4.618.
5
The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans.克拉霉素和罗红霉素在人体鼻黏膜、扁桃体及肺部的扩散情况。
J Antimicrob Chemother. 1991 Feb;27 Suppl A:61-5. doi: 10.1093/jac/27.suppl_a.61.
6
Tissue-directed pharmacokinetics.
Am J Med. 1991 Sep 12;91(3A):5S-11S. doi: 10.1016/0002-9343(91)90394-d.
7
Persistent infection with Chlamydia pneumoniae following acute respiratory illness.急性呼吸道疾病后肺炎衣原体的持续感染。
Clin Infect Dis. 1992 Jan;14(1):178-82. doi: 10.1093/clinids/14.1.178.
8
In vitro activities of five quinolones against Chlamydia pneumoniae.五种喹诺酮类药物对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1992 Mar;36(3):682-3. doi: 10.1128/AAC.36.3.682.
9
In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.阿奇霉素、红霉素和四环素对沙眼衣原体和肺炎衣原体活性的体外评估
Antimicrob Agents Chemother. 1992 Feb;36(2):291-4. doi: 10.1128/AAC.36.2.291.
Zotero 插件